Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 8, 2013, Pages

  Ghossein, Ronald A ^a   Katabi, Nora ^a   Fagin, James A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BRAF V600E PROTEIN; DNA; UNCLASSIFIED DRUG;

ARTICLE; BRAF GENE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; GENE MUTATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MOLECULAR CLONING; POORLY DIFFERENTIATED THYROID CANCER; PRIORITY JOURNAL; THYROID CARCINOMA; TISSUE MICROARRAY; WILD TYPE;

DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 84881512900     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1408     Document Type: Article

References (34)

1. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7:569-580.
2. Kimura ET, NikiforovaMN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003; 63:1454-1457.
3. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95:625-627.
4. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/ PTCrearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003;22:4578-4580.
5. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399-5404.
6. Puxeddu E, Moretti S, Elisei R, et al. BRAFV599E mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab. 2004;89:2414-2420.
7. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12:245-262.
8. Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009;69:4885-4893.
9. Basolo F, Torregrossa L, Giannini R, et al. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab. 2010;95:4197-4205.
10. Elisei R, Ugolini C, Viola D, et al.BRAFV600E mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab. 2008;93:3943-3949.
11. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spotBRAFmutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab. 2003;88:4393-4397.
12. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007; 28:742-762.
13. Fugazzola L, Puxeddu E, Avenia N, et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer. 2006;13:455-464.
14. Ito Y, Yoshida H, Maruo R, et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J. 2009;56:89-97.
15. Koperek O, Kornauth C, Capper D, et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol. 2012;36:844-850.
16. Lee HJ, Choi J, Hwang TS, Shong YK, Hong SJ, Gong G. Detection of BRAF mutations in thyroid nodules by allele-specific PCR using a dual priming oligonucleotide system.AmJ Clin Pathol. 2010;133: 802-808.
17. Guerra A, Sapio MR, Marotta V, et al. The primary occurrence of BRAFV600E is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012;97:517-524.
18. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011;122:11-19.
19. DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. Pathology & Genetics. Tumours of the Endocrine Organs, 3rd ed. Lyon, France: IARC Press; 2004. World Health Organization Classification of Tumour; vol 8.
20. Hiltzik D, Carlson DL, Tuttle RM, et al. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer 2006;106:1286-1295.
21. Hoos A, Urist MJ, Stojadinovic A, et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors.AmJ Pathol. 2001; 158:1245-1251.
22. Saltman B, Singh B, Hedvat CV, Wreesmann VB, Ghossein R. Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression. Surgery 2006;140:899-905; discussion 905-896.
23. Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol. 2008;21(suppl 2):S37-S43.
24. Rivera M, Ricarte-Filho J, Knauf J, et al. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol. 2010;23:1191-1200.
25. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363: 809-819.
26. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
27. Kim SH, Lewis JJ, Brennan MF, et al. Overexpression of cyclin D1 is associated with poor prognosis in extremity soft-tissue sarcomas. Clin Cancer Res. 1998;4:2377-2382.
28. Wu H, Wu W, Chen Z, et al. Highly sensitive pyrosequencing based on the capture of free adenosine 5' phosphosulfate with adenosine triphosphate sulfurylase. Anal Chem. 2011;83:3600-3605.
29. Capper D, Berghoff AS, Magerle M, et al. Immunohistochemical testing of BRAF V600E status in 1, 120 tumor tissue samples of patients with brain metastases. Acta Neuropathol. 2012;123:223-233.
30. Frattini M, Ferrario C, Bressan P, et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene. 2004;23:7436-7440.
31. Sarne DH. A piece of the puzzle: what does BRAF status mean in the management of patients with papillary thyroid carcinoma? J Clin Endocrinol Metab. 2012;97:3094-3096.
32. Franco AT, Malaguarnera R, Refetoff S, et al. Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci USA. 2011;108:1615-1620.
33. Charles RP, Iezza G, Amendola E, Dankort D, McMahon M. Mutationally activatedBRAFV600E elicits papillary thyroid cancer in the adult mouse. Cancer Res. 2011;71:3863-3871.
34. Giordano T. Papillary thyroid carcinoma analysis. Paper presented at: The Cancer Genome Atlas' 2nd Annual Scientific Symposium: Enabling Cancer Research Through TCGA; November 27-28, 2012; Crystal City, VA.